---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-26-000855"
form_type: "8-K"
ticker: "PKTX"
cik: "0001128189"
company_name: "ProtoKinetix, Inc."
filed_at: "2026-06-17T21:28:41+00:00"
generated_at: "2026-06-17T21:30:34.569025+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProtoKinetix appoints new President, forms SightPath Biotech, patents valued at $253M

## Summary
- Director McDonough resigned March 31; June 17: Jones, Lamp, Brunt appointed directors, Brunt as President.
- Formed SightPath Biotech LLC for dry-eye drug PKX-001; patent valuation ~$253M per IQVIA & Benoit & Cote studies.
- Late filings: 2025 10-K (Mar 31) and Q1 2026 10-Q (May 15); company still working to complete.
- Repriced 61.19M options and 6M warrants from $0.028 to $0.01, extended expiry to Dec 2030.

## SEC filing metadata
- accession: 0001079973-26-000855
- form_type: 8-K
- ticker: PKTX
- cik: 0001128189
- company_name: ProtoKinetix, Inc.
- filed_at: 2026-06-17T21:28:41+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/pktx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-26-000855
- JSON: https://secwatch.observer/filing/0001079973-26-000855.json
- Plain text: https://secwatch.observer/filing/0001079973-26-000855.txt

## Key facts
- Executive change
  Edward McDonough resigned as Director at ProtoKinetix, Inc..
  - Action: resigned
  - Role: Director
  source text: On March 31, 2026, Mr. Edward McDonough, after serving many years as a trusted advisor to ProtoKinetix, Incorporated (the “Company”) under the leadership of Clarence E. Smith, notified the Board of Directors of the Company (the “Board”) of his resignation from the Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
- Executive change
  Keith Brunt was appointed as Director at ProtoKinetix, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
- Executive change
  Keith Brunt was appointed as President at ProtoKinetix, Inc..
  - Action: appointed
  - Role: President
  source text: On June 17, 2026, Keith Brunt, a Translational Scientist and Associate Professor of Pharmacology, in the Faculty of Medicine at Dalhousie Medicine in New Brunswick, was appointed as a director and as the president of the Company, to hold such office until his successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
- Executive change
  Michael Jones was appointed as Director at ProtoKinetix, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm
- Executive change
  Jason Lamp was appointed as Director at ProtoKinetix, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 17, 2026, Michael Jones, of Corbin, Kentucky, and Jason Lamp, of Roswell, Georgia were appointed as directors of the Company to serve as members of the Board, and to hold such office until their successors are duly elected and qualified.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1128189/000107997326000855/0001079973-26-000855-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.